{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:52:15Z","timestamp":1791910335068,"version":"4.3.4"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.vaccine.2026.129191","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:29:52Z","timestamp":1791408592000},"page":"129191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Sequence-Aware Antigenic Alignment and SRID Potency Interpretation in Influenza Vaccines"],"prefix":"10.1016","volume":"93","author":[{"given":"Ohseok","family":"Jeong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan-kyeom","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hookeun","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunse","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Hwan","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.129191_bb0005","series-title":"WHO expert committee on biological standardization: sixty-second report. WHO technical report series vol. No. 979","author":"World Health Organization","year":"2012"},{"key":"10.1016\/j.vaccine.2026.129191_bb0010","unstructured":"National Institute for biological standards and control (NIBSC). Influenza potency testing (SRID gold standard; reagents; ERL calibration) [Internet]. Potters Bar: NIBSC; c2024 [cited 2026 May 10]. Available from: https:\/\/www.nibsc.org\/science_and_research\/virology\/influenza_resource_\/influenza_potency_testing.aspx."},{"key":"10.1016\/j.vaccine.2026.129191_bb0015","series-title":"Guideline on influenza vaccines - quality module [internet]","author":"European Medicines Agency","year":"2017"},{"key":"10.1016\/j.vaccine.2026.129191_bb0020","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0378-1135(93)90027-5","article-title":"Single-radial-immunodiffusion as an in vitro potency assay for human inactivated viral vaccines","volume":"37","author":"Williams","year":"1993","journal-title":"Vet. Microbiol."},{"key":"10.1016\/j.vaccine.2026.129191_bb0025","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1080\/21645515.2015.1026497","article-title":"The development and manufacture of influenza vaccines","volume":"11","author":"Buckland","year":"2015","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.vaccine.2026.129191_bb0030","doi-asserted-by":"crossref","first-page":"5913","DOI":"10.1016\/j.vaccine.2015.07.104","article-title":"Critical review of current and emerging quantification methods for the development of influenza vaccine candidates","volume":"33","author":"Manceur","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129191_bb0035","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1128683","article-title":"Rapid determination of influenza vaccine potency by an SPR-based method using subtype or lineage-specific monoclonal antibodies","volume":"14","author":"Narayan","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.vaccine.2026.129191_bb0040","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1696191","article-title":"Utilisation of monoclonal antibodies in the single radial immunodiffusion assay to determine potency and stability for seasonal and pandemic influenza vaccines","volume":"16","author":"Bodle","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.vaccine.2026.129191_bb0045","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00253-024-13145-y","article-title":"Antibody-independent surface plasmon resonance assays for influenza vaccine quality control","volume":"108","author":"Serafin","year":"2024","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.vaccine.2026.129191_bb0050","doi-asserted-by":"crossref","DOI":"10.1038\/srep15279","article-title":"H3N2 mismatch of 2014-15 northern hemisphere influenza vaccines and head-to-head comparison between human and ferret antisera derived antigenic maps","volume":"5","author":"Xie","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.vaccine.2026.129191_bb0055","doi-asserted-by":"crossref","first-page":"56","DOI":"10.7774\/cevr.2020.9.1.56","article-title":"Comparison of antigenic mutation during egg and cell passage cultivation of H3N2 influenza virus","volume":"9","author":"Park","year":"2020","journal-title":"Clin Exp Vaccine Res"},{"key":"10.1016\/j.vaccine.2026.129191_bb0060","doi-asserted-by":"crossref","DOI":"10.1093\/molbev\/msaf227","article-title":"Seasonal influenza viruses show distinct adaptive dynamics during growth in chicken eggs","volume":"42","author":"Kistler","year":"2025","journal-title":"Mol. Biol. Evol."},{"key":"10.1016\/j.vaccine.2026.129191_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010875","article-title":"Egg-adaptive mutations of human influenza H3N2 virus are contingent on natural evolution","volume":"18","author":"Liang","year":"2022","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.vaccine.2026.129191_bb0070","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1146\/annurev.biochem.69.1.531","article-title":"Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin","volume":"69","author":"Skehel","year":"2000","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.vaccine.2026.129191_bb0075","doi-asserted-by":"crossref","first-page":"12578","DOI":"10.1073\/pnas.1712377114","article-title":"Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains","volume":"114","author":"Zost","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.vaccine.2026.129191_bb0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0092153","article-title":"Low 2012\u201313 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses","volume":"9","author":"Skowronski","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2026.129191_bb0085","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1007\/s40121-025-01230-2","article-title":"Superior effectiveness and estimated public health impact of cell- versus egg-based influenza vaccines in children and adults during the US 2023\u20132024 season","volume":"14","author":"Stein","year":"2025","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.vaccine.2026.129191_bb0090","series-title":"WHO information meeting - composition of influenza virus vaccines - 2022-2023 northern hemisphere [internet]","author":"World Health Organization","year":"2022"},{"key":"10.1016\/j.vaccine.2026.129191_bb0095","series-title":"WHO information meeting - influenza virus vaccine composition for 2023 southern hemisphere [internet]","author":"World Health Organization","year":"2022"},{"key":"10.1016\/j.vaccine.2026.129191_bb0100","series-title":"WHO recommendation on influenza vaccine composition northern hemisphere 2023\u20132024 [internet]","author":"World Health Organization","year":"2023"},{"key":"10.1016\/j.vaccine.2026.129191_bb0105","series-title":"WHO information meeting - influenza virus vaccines composition for 2024 southern hemisphere [internet]","author":"World Health Organization","year":"2023"},{"key":"10.1016\/j.vaccine.2026.129191_bb0110","series-title":"WHO information meeting - influenza virus vaccine composition for 2024\u20132025 northern hemisphere [internet]","author":"World Health Organization","year":"2024"},{"key":"10.1016\/j.vaccine.2026.129191_bb0115","series-title":"WHO information meeting - influenza virus vaccines composition for 2025 southern hemisphere [internet]","author":"World Health Organization","year":"2024"},{"key":"10.1016\/j.vaccine.2026.129191_bb0120","series-title":"WHO meeting on 2025\u20132026 northern hemisphere influenza vaccine composition [internet]","author":"World Health Organization","year":"2025"},{"key":"10.1016\/j.vaccine.2026.129191_bb0125","series-title":"WHO information meeting - influenza virus vaccines composition for 2026 southern hemisphere [internet]","author":"World Health Organization","year":"2025"},{"key":"10.1016\/j.vaccine.2026.129191_bb0130","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-018-0079-z","article-title":"Cell culture-derived influenza vaccines in the severe 2017-2018 epidemic season: a step toward improved influenza vaccine effectiveness","volume":"3","author":"Barr","year":"2018","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2026.129191_bb0135","series-title":"Potency determination of inactivated influenza virus vaccines and testing of influenza reagents by the SRID method [internet]","author":"U.S. Food and Drug Administration","year":"2024"},{"key":"10.1016\/j.vaccine.2026.129191_bb0140","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/irv.12543","article-title":"Standardisation of inactivated influenza vaccines-learning from history","volume":"12","author":"Wood","year":"2018","journal-title":"Influenza Other Respir. Viruses"},{"key":"10.1016\/j.vaccine.2026.129191_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2026.128235","article-title":"Bromelain-cleaved hemagglutinin production from cell culture-derived influenza viruses enhances vaccine potency quantification by single radial immunodiffusion assay","volume":"75","author":"Jeong","year":"2026","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129191_bb0150","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1126\/science.1244730","article-title":"Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution","volume":"342","author":"Koel","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2026.129191_bb0155","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy209.164","article-title":"Retrospective evaluation of mismatch from egg-based isolation of influenza strains compared with cell-based isolation and the possible implications for vaccine effectiveness","volume":"5","author":"Rajaram","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.vaccine.2026.129191_bb0160","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a038638","article-title":"Hemagglutinin structure and activities","volume":"11","author":"Gamblin","year":"2021","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.vaccine.2026.129191_bb0165","doi-asserted-by":"crossref","DOI":"10.3390\/v15041008","article-title":"Structural consequences of antigenic variants of human a\/H3N2 influenza viruses","volume":"15","author":"Burke","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2026.129191_bb0170","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1080\/21645515.2020.1721223","article-title":"Development and characterization of standard reagents for cell-based prepandemic influenza vaccine products","volume":"16","author":"Lai","year":"2020","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.vaccine.2026.129191_bb0175","doi-asserted-by":"crossref","unstructured":"Donohue MP, Cao Z, Bowen T, Dickinson R, Zhang Y, Qian J, et al. The CombE-IDMS alternate potency method for H5N1 and H5N8 cell-based vaccines. Vaccines 2023;11:1799.","DOI":"10.3390\/vaccines11121799"},{"key":"10.1016\/j.vaccine.2026.129191_bb0180","doi-asserted-by":"crossref","first-page":"11879","DOI":"10.1021\/acs.analchem.0c02252","article-title":"Limited tryptic digestion-isotope dilution mass spectrometry (LTD-IDMS): a reagent-free analytical assay to quantify hemagglutinin of a(H5N1) vaccine material","volume":"92","author":"Cooper","year":"2020","journal-title":"Anal. Chem."},{"key":"10.1016\/j.vaccine.2026.129191_bb0185","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41541-018-0080-6","article-title":"VaxArray potency assay for rapid assessment of pandemic influenza vaccines","volume":"3","author":"Byrne-Nash","year":"2018","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2026.129191_bb0190","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1016\/j.vaccine.2023.06.051","article-title":"Assessing the stability-indicating properties of alternative potency assays for inactivated influenza vaccine","volume":"41","author":"Ekimov","year":"2023","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26010005?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26010005?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:22:40Z","timestamp":1791908560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26010005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":38,"alternative-id":["S0264410X26010005"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129191","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sequence-Aware Antigenic Alignment and SRID Potency Interpretation in Influenza Vaccines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129191","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"129191"}}